WFL Stock Overview
Wellfully Limited, together with its subsidiaries, focuses on the development and commercialization of Dermaportation and ETP transdermal drug delivery technologies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Wellfully Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.003 |
| 52 Week High | AU$0.027 |
| 52 Week Low | AU$0.001 |
| Beta | -0.91 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -86.96% |
| 33 Year Change | -98.38% |
| 5 Year Change | -99.25% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| WFL | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -11.8% | 1.5% |
| 1Y | -87.0% | 39.8% | 17.2% |
Return vs Industry: WFL underperformed the Australian Pharmaceuticals industry which returned 61.8% over the past year.
Return vs Market: WFL underperformed the Australian Market which returned 9.6% over the past year.
Price Volatility
| WFL volatility | |
|---|---|
| WFL Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: WFL's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine WFL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | n/a | Paul Peros | www.wellfully.net |
Wellfully Limited, together with its subsidiaries, focuses on the development and commercialization of Dermaportation and ETP transdermal drug delivery technologies. It operates in two segments, Dermaportation Drug Delivery Technology and Devices. The company is also involved in the industrialization and supply-chain support for its existing product ranges; and sale and marketing of its own brands REDUIT and SWISSWELL, as well as third-party collaborations.
Wellfully Limited Fundamentals Summary
| WFL fundamental statistics | |
|---|---|
| Market cap | AU$1.48m |
| Earnings (TTM) | -AU$7.80m |
| Revenue (TTM) | AU$1.66m |
0.9x
P/S Ratio-0.2x
P/E RatioIs WFL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WFL income statement (TTM) | |
|---|---|
| Revenue | AU$1.66m |
| Cost of Revenue | AU$1.86m |
| Gross Profit | -AU$200.41k |
| Other Expenses | AU$7.60m |
| Earnings | -AU$7.80m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | -12.05% |
| Net Profit Margin | -469.00% |
| Debt/Equity Ratio | -98.7% |
How did WFL perform over the long term?
See historical performance and comparison